Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma

Summary

The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.

Eligibility

Inclusion Criteria:

* Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen
* Agreement to participate after receiving oral and written information on the study

Exclusion Criteria:

* History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma)
* Treatment with a chemotherapy regimen different from RCHOP21

Conditions3

Interventions1

Related trials

• Analysis of Circulating Tumor Markers in Blood — Institut du Cancer de Montpellier - Val d'Aurelle
• B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer. — Poitiers University Hospital
• Biobank for Inflammatory Chronic Diseases and Osteoporosis — University Hospital, Toulouse
• Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer. — Hospices Civils de Lyon
• Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis — Assistance Publique - Hôpitaux de Paris
• Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer — Hospices Civils de Lyon
• Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases — University Hospital, Toulouse
• Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases — University Hospital, Toulouse

Browse More Trials